High Prevalence of Chronic Diseases and Increasing Investment in Organ Preservation to Augment Growth of Organ Preservation Market
Organ preservation plays a major role in organ transplant and treatment and management of chronic diseases. It can be used to preserve organs such as the liver, pancreas, and kidneys. Organ preservation can be used to preserve organs for around 72 hours.
Market Dynamics
High
prevalence of chronic diseases is expected to propel growth of the organ preservation market. For instance, the U.S is expected to record 1,806,590 new
cases of cancer and 606,520 deaths from the disease in 2020, according to National
Cancer Institute. Moreover, high demand for organ transplant is also expected
to boost growth of the organ preservation market. For instance, according to the U.S. Government
Information on Organ Donation and Transplantation, over 112,000 patients are on
the national transplant waiting list as of March 2020.
Increasing
investment in organ preservation is expected to offer lucrative growth
opportunities for players in the organ preservation market. For instance, in
January 2020, BGF, a U.K and Ireland-focused SME investor, offered US$ 6.38
million to OrganOx, a medtech solutions provider, for launch of its first
product.
There
are some limitations in organ preservation, which is expected to hinder growth
of the organ preservation market. These limitations include, tissue damage,
difficulty in assessing donor organ function, and limited opportunity for organ
repair.
North
America is expected to witness significant growth in the organ preservation
market, owing to increasing number of organ transplants in the region. For
instance, according to American Heart Association 2019 Heart Disease and Stroke
Statistics, 1,016,000 cardiac catheterizations and 3,244 heart transplants were
performed in the U.S. in 2014 and 2017, respectively. Moreover, increasing adoption of organ
preservation devices in the military and defense sector is also expected to
propel growth of the market in the region. For instance, in 2019, Department of
Defense, U.S. Federal Government, announced to use limb, organ preservation
devices in various experiments.
Asia
Pacific is expected to witness significant growth in the organ preservation market,
owing to low cost of healthcare facilities in the region.
Competitive Analysis
Major
players operating in the global organ preservation market include, Teva
Pharmaceutical Industries Ltd., Dr. Franz Vascular Perfusion Solutions, Inc., Köhler
Chemie GmbH, BioLife Solutions, XVIVO Perfusion AB, Bristol-Myers Squibb, Inc.,
and ToleroTech, Inc., Lifeline Scientific, Preservation Solutions Inc., Claris
Injectables Limited, 21st Century Medicine, Paragonix Technologies Inc.,
BioTime, Inc. CryoLife, Inc., Bridge to Life, Ltd., and Dr. Franz Köhler Chemie
GmbH.
Major
players operating in the global organ preservation market are focused on
adopting M&A strategies to expand their product portfolio. For instance, in
February 2021, Bridge to Life, Ltd. merged with Tevosol, Inc., a clinical stage
medical device startup, to develop and commercialize new products for the organ
transplantation.
Major
players operating in the global organ preservation market are also focused on
approval and launch of new products to expand their product portfolio. For
instance, in February 2021, Vascular Perfusion Solutions, Inc. was granted the
U.S. FDA Breakthrough Device Designation for VP.S Encore oxygenated perfusion
cardiac transport device.
Comments
Post a Comment